Endeavour et al. lead $25m series-D for Endostim

According to a statement, European private equity house Gimv provided $2.7m of capital to the round. Existing investor Santé Ventures also participated to the round.

The fresh capital will boost the company's expansion and commercialisation strategies, as well as enable the business to conduct its clinical trial for the US market.

As part of the deal, Endeavour investment director Alexander Schmitz will join the company's management board.

Company
Endostim is a medical device developer, founded in 2009 and co-headquartered in Missouri and Nijmegen, the Netherlands. The business focuses on neurostimulation therapies for gastroesophageal reflux disease.

The company's product is already available across Europe, Latin America and Asia.

People
Endeavour Vision – Alexander Schmitz (investment director).
Gimv – Patrick Van Beneden (partner).
Santé Ventures – Douglas French (managing director).
Endostim – Douglas French (chair).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• Healthcare
• Benelux
• Netherlands
• Gimv
• Wellington Partners